154 related articles for article (PubMed ID: 36809598)
21. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
Borte M; Hanitsch LG; Mahlaoui N; Fasshauer M; Huscher D; Speletas M; Dimou M; Kamieniak M; Hermann C; Pittrow D; Milito C
J Clin Immunol; 2023 Aug; 43(6):1259-1271. PubMed ID: 37036560
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study.
Kanegane H; Endo A; Okada S; Ohnishi H; Ishimura M; Nishikomori R; Imai K; Nonoyama S; Muramatsu H; Wada T; Kuga A; Sakamoto K; Russo-Schwarzbaum S; Chu LH; McCoy B; Li Z; Yel L
Immunother Adv; 2024; 4(1):ltae001. PubMed ID: 38511087
[TBL] [Abstract][Full Text] [Related]
23. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency.
Gupta S; Kobayashi RH; Litzman J; Cherwin L; Hoeller S; Kreuwel H
Expert Rev Clin Immunol; 2023 Jan; 19(1):7-17. PubMed ID: 36346032
[TBL] [Abstract][Full Text] [Related]
24. Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.
Bienvenu B; Cozon G; Mataix Y; Lachaud D; Alix A; Hoarau C; Antier D; Hachulla E; Brice S; Viallard JF; Tamisier S; Fauchais AL; Renon-Carron F; Clerson P; Fardini Y; Crave JC; Miossec P
J Clin Immunol; 2018 May; 38(4):503-512. PubMed ID: 29855752
[TBL] [Abstract][Full Text] [Related]
25. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J
Front Immunol; 2019; 10():40. PubMed ID: 30778345
[No Abstract] [Full Text] [Related]
26. Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases.
Li Z; Dumas T; Seth Berry N; McCoy B; Yel L
Int Immunopharmacol; 2021 Nov; 100():108044. PubMed ID: 34601202
[TBL] [Abstract][Full Text] [Related]
27. Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study.
Anderson JT; Bonagura VR; Cowan J; Hsu C; Mustafa SS; Patel NC; Routes JM; Sriaroon P; Vinh DC; Hofmann JH; Praus M; Rojavin MA
J Clin Immunol; 2021 Feb; 41(2):458-469. PubMed ID: 33409867
[TBL] [Abstract][Full Text] [Related]
28. A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency.
Santamaria M; Neth O; Douglass JA; Krivan G; Kobbe R; Bernatowska E; Grigoriadou S; Bethune C; Chandra A; Horneff G; Borte M; Sonnenschein A; Kralickova P; Ramón SS; Langguth D; Gonzalez-Granado LI; Alsina L; Querolt M; Griffin R; Hames C; Mondou E; Price J; Sanz A; Lin J
J Clin Immunol; 2022 Apr; 42(3):500-511. PubMed ID: 34973143
[TBL] [Abstract][Full Text] [Related]
29. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
[TBL] [Abstract][Full Text] [Related]
30. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
Sriaroon P; Ballow M
Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
[TBL] [Abstract][Full Text] [Related]
31. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
32. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
34. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies.
Perez EE; Hébert J; Ellis AK; Alpan O; Lumry WR; Shapiro R; Suez D; Mandujano JF; Wasserman RL
Front Immunol; 2021; 12():707463. PubMed ID: 34305948
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.
Ochs HD; Gupta S; Kiessling P; Nicolay U; Berger M;
J Clin Immunol; 2006 May; 26(3):265-73. PubMed ID: 16783465
[TBL] [Abstract][Full Text] [Related]
37. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
McCormack PL
BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
[TBL] [Abstract][Full Text] [Related]
38. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous immunoglobulin use in immunoglobulin-naive patients with primary immunodeficiency: a systematic review.
Anderson-Smits C; Park M; Bell J; Mitchell S; Hartley L; Hawe E
Immunotherapy; 2022 Apr; 14(5):373-387. PubMed ID: 35128932
[No Abstract] [Full Text] [Related]
40. Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(
Angelotti F; Capecchi R; Giannini D; Mazzarella O; Rocchi V; Migliorini P
Clin Exp Med; 2020 Aug; 20(3):387-392. PubMed ID: 32385734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
